Combinations of gentamicin with cefotaxime, moxalactam, and ceftazidime were tested against 43 bacterial strains, most of them blood isolates. With an interaction index of 0.5 as borderline, synergism was demonstrated against 30 to 40% of the strains by the fractional inhibitory concentration index and against 50 to 70% by the fractional bactericidal concentration index. The reproducibility of the index was within ±0.2 for two-thirds of 40 repetitive assays and within ±0.4 to 0.5 for all of these assays. Similar results were obtained when netilmicin was substituted for gentamicin. The killing curve system for studying antibiotic synergism was standardized to give results comparable to those obtained with the interaction index. This was achieved when one-half of a previously determined minimum bactericidal concentration was used for single drugs and the amount of antibiotic was at least halved again when drugs were used in combination. An initial bacterial concentration of 105 to 106 colony-forming units per ml is recommended. Given these conditions, synergism could be defined as a 2-log10 or more decrease in viable count given by both drugs together, as compared with the more active of the pair after 24 h. Prediction of killing curve results could then be obtained with the fractional bactericidal concentration index. When cephalosporins and gentamicin were combined from the start, the beta-lactam antibiotics were less susceptible to inactivation, as demonstrated in time-killing assays. If one of the antibiotics were added after 24 h, synergism was not demonstrable. The results indicate that the new cephalosporins may be advantageously combined with aminoglycosides.
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Evidence is accumulating that infections in immunocompromised patients may cause fewer deaths if they are treated with synergistic combinations of antibiotics rather than nonsynergistic combinations (12, 14, 31, 33) . Such combinations are usually comprised of a penicillin or a cephalosporin and an aminoglycoside.
The development of highly active beta-lactam antibiotics with broad antibacterial spectra, including activity against Pseudomonas aeruginosa (5, 10, 23) , has led to a tendency to replace the former combinations by single-drug therapy. It is therefore essential that the efficacy of these drugs used singly be weighed against their potential synergistic capacity.
Most data on synergistic action are based on in vitro observations. The time-kill curve, determining lethal effect, and the checkerboard titration method, giving bacteriostatic as well as bactericidal results, are two basic techniques for quantitative assessment of synergism (2, 8, 15, 21, 32) . In a modification of the checkerboard method proposed by Berenbaum (3) , the two drugs are mixed in fractions of their minimum inhibitory concentrations (MICs) for each bacterial strain and serially diluted.
The results of synergism testing are variable, however, depending on differences in technique and a multiplicity of laboratory definitions of synergism. Norden et al. (22) demonstrated a lack of correlation between different methods for assaying synergy against Klebsiella strains. Similar data were reported for enterococci by Ryan et al. (27) . On the other hand, Weinstein et al. (30) found excellent correlation between the methods in question.
The present study concerned the in vitro effect of cefotaxime, ceftazidime, and moxalactam, singly and in combination with gentamicin or netilmicin. For some bacterial strains, calculations of interaction index were compared with results obtained from killing curves. Factors influencing results and comparability were analyzed.
MATERIALS AND METHODS Bacterial strain. Forty-three strains were used: 22 P. aeruginosa, 1 Pseudomonas maltophilia, 4 Escherichia coli, 1 Enterobacter species, 1 Citrobacter species, 1 Proteus mirabilis, 3 Serratia species, 1 Providencia species, and 9 Staphylococcus species. Most were blood isolates from patients with septicemia, e.g., P. maltophilia SI164 and P. aeruginosa SII88. Some were selected strains of P. aeruginosa, representing various types of enzymatic resistance to aminoglycosides. Strain PAO1 (9) (Fig. lb) . In another experiment, this result was not obtained (Fig. 2) of CFU effected by the combination, as compared with each constituent drug. This is exemplified by the combination gentamicin-cefotaxime against P. aeruginosa PAQ1 (Fig. la to c) . Concentrations that were too low resulted in regrowth in the presence of each drug, as well as with the combination (Fig. la) , and concentrations higher than the MBC gave bacterial killing throughout (Fig. lc) . The initial concentration of the individual drugs should therefore be close to the expected inhibitory level that still permits regrowth (Fig. lb) of the respective antibiotic concentrations to 2 and 16 ,ug/ml, however, eliminated the differences at 24 h, even though the drugs were still effective after 4 and 6 h. To ensure that the observed effect is not only an additive effect, the amount of each constituent in the combination should be no more than one-half the concentration used for that drug alone.
(iii) Effect of inoculum size. The initial inoculum was varied from 102 to 103 to 106 to 107 CFU/ml (Fig. 3a to c) . With the lower inoculum, the killing effect of single antibiotics was so pronounced that synergism could not be demonstrated. With an inoculum of 106 to 107 CFU/ml, on the other hand, conditions for regrowth seemed to be established when the drugs were used separately at the MIC (Fig. 3c) (Fig.  1 to 4) . Inhibition of regrowth in the combination as compared with the most effective constituent after 24 h seems to be the most reliable indicator of synergism with the killing curve method.
(vi) Reproducibility of killing curves. Reproducibility of synergism measured by the killing curve method is affected by the amount of antibiotics used in the combination. With con- centrations well within the limits of lethal activity, the reproducibility is good (Table 6 ). When low concentrations close to the endpoints of synergistic capacity are chosen, the reproducibility is more uncertain (compare Fig. lb and 2 ). Repeated experiments with PAO1 and the combination gentamicin-cefotaxime, however, indicate that a 2-log1o difference or more between the combination and its most active constituent after 24 h may be used as an indicator of synergism.
Second-dose effect: exposed and nonexposed cultures. The laboratory model does not take into account the fact that the drugs are given repeatedly over several days. Furthermore, therapy is often initiated with one antibiotic, and others are added later.
(i) Synergism. The situation in which therapy is begun with one antibiotic and then others are added was mimicked in killing curve experiments with gentamicin plus cefotaxime, moxalactam, or ceftazidime. P. aeruginosa PAO1 was grown with the antibiotic separately and in combinations. Similar results were obtained with all three combinations. The gentamicin-moxalactam combination (YFBC = 0.51) (Fig. 4) illustrates the steady bacterial decrease that occurred over 24 h in response to gentamicinmoxalactam, whereas with each antibiotic alone there was regrowth between 6 and 24 h (Fig. 4a) .
After 24 h, bacteria were sampled as inocula for new, identical runs ( Fig. 4b to d) . To obtain appropriate inocula (105 to 106 CFU/ml) from the combinations, however, bacteria from such vials were sampled at 6 h and then were grown in 1/16 MBC plus 1/16 MBC before use in the day 2 experiment. Bacteria exposed to moxalactam (Fig. 4c) or to gentamicin (Fig. 4d) were no longer inhibited by the respective antibiotics, although they remained susceptible to the other (Fig. 4b ) remained synergistically inhibited by the combination after 4 h and after 24 h (Table 7) . They were also susceptible after 4 and 6 h to both constituents tested separately.
(ii) Antibiotic inactivation. Parallel with colony counting, samples were taken for assay of residual amounts of antibiotic (Table 7) . In general, inactivation of antibiotics was followed by regrowth. With moxalactam, there was a reduction in the concentration sufficient for regrowth, but not total inactivation, except when the moxalactam-exposed culture had been grown with moxalactam alone on day 2. Cefotaxime, on the other hand, was completely inactivated, except after 24 h, when used in combination with gentamicin and after 48 h in the same combination against bacteria exposed to cefotaxime plus gentamicin. The results may suggest differences in killing effect between the cephalosporins. However, the experiments were not identical with regard to inocula and initial antibiotic concentrations. Moreover, gentamicin activity was reduced and regrowth observed when the drug was used separately against a culture exposed to gentamicin for 24 h (Table 7) (25) 100 (23) 100 (12) Such interaction may be clinically useful, particularly in situations in which host defense mechanisms are depressed, when bacterial killing may depend wholly on the antimicrobial potency of the antibiotics administered. In the present study, the MBCs for 50% of strains were 16 to 32 ,ug/ml when the antibiotics were tested individually, but these concentrations could be reduced to 4 or 8,ug/ml in synergistic action.
When the MIC was used for calculating the interaction index, only 30 to 40% of the strains showed synergism, and >IFIC did not predict results in time-kill assays. In the checkerboard technique, however, the endpoint is usually defined as the MIC after overnight incubation. This may be one explanation of the discrepancies described by Norden et al. (22) . A few investigators have used the MBC to study antibiotic synergism (1, 13, 30) .
Since the time-kill assay measures bactericidal activity in relation to time, it is logical that results obtained with this method after overnight incubation should be viewed in relation to interaction indices calculated from MBCs. King et al. (11) advocated the use of a growth rate constant obtained from empirical dose-response curves.
To provide optimal and comparable results, the killing curve method must be adequately standardized. In the literature, various criteria for synergism in time-killing assays have been used, from 1 logl0 between the combination and the most effective constituent after 4 h (6, 19) to 2 log10 (22) or more than 3 log10 (30) increased killing after 24 h. Data presented in this report support a difference of 2 logl0 or more after 24 h with one-half the MBC of the drugs used alone and the amount of antibiotic at least halved in the combination. An incubation time of 24 h and an inoculum of 105 to 106 CFU/ml are similar to conditions used in susceptibility testing and with the checkerboard technique.
One of the most intriguing questions is whether in vitro synergism is associated with improved clinical outcome. Young (31) reported such a positive association from a prospective, randomized study on gentamicin-carbenicillin versus amikacin-carbenicillin in neutropenic patients. Klastersky and Zinner (14) reviewed data showing a favorable clinical response in 113 (79%) of 149 cancer or neutropenic patients when synergistic combinations of antibiotics were used against severe infections, but in only 64 (45%) of 143 patients when the combinations were nonsynergistic. A combination of the new broad-spectrum cephalosporins with aminoglycosides may be advantageous. Further studies must be undertaken, however, to determine whether these new antibiotics also give better clinical results in combination than when used separately.
